Therefore, as proposed for AD, Wnt activators that restore Wnt/β-catenin signalling in brain, particularly those targeting Wnt antagonist DKK1 and Wnt receptor LRP6, could represent novel therapeutic tools for migraine treatment. This evidence concerns the gene LRP6 and migraine disorder.